Soligenix put out their Q3 update, and with small biotechs like this it’s always kind of a gamble. Even a little progress or new funding news can really move SNGX since the company’s so small. I'm not in a position to make any major risks, so I'll sit it out, for now at least.
There are no replies in this thread yet. Be the first to post a reply below: